Pay in 4 interest-free payments of $5.37 Learn more
Ships within 48 hours · Estimated delivery Sep 9 - Sep 14
Clinical Trial Results STEP Trials (Semaglutide) The STEP program studied semaglutide 2.4 mg weekly in overweight/obese adults: STEP 1 : 16.9% average weight loss over 68 weeks vs 2.4% placebo STEP 2 (T2D patients): 9.6% weight loss STEP 3 (with behavioral therapy): 16.0% weight loss STEP 5 (2-year data): 15.2% sustained weight loss SURMOUNT Trials (Tirzepatide) The SURMOUNT program studied tirzepatide at 5mg, 10mg, and 15mg weekly: SURMOUNT-1 : 20.9% average weight loss at 15mg over 72 weeks vs 3.1% placebo SURMOUNT-2 (T2D patients): 14.7% at 15mg SURMOUNT-3 (with lifestyle intervention): 26.6% at highest dose SURMOUNT-4 (maintenance): continued weight loss vs weight regain on placebo Head-to-Head No large head-to-head trial has directly compared them at optimal doses for weight loss
Although Golo Releases magnesium content is relatively low compared to some recommended dosages, supplementation can improve general health and potentially assist with insulin resistance
It plays a key role in energy production by transporting fatty acids into the mitochondria, where they are converted into fuel
Discrepancies were resolved through collegial discussions
US$ 28.62
US$ 26.39
US$ 20.82
US$ 22.92
US$ 20.67
US$ 21.85
US$ 20.89
US$ 23.32
US$ 23.13
US$ 25.77
US$ 28.25
US$ 20.01
